Venture Life Group (LON:VLG) Stock Crosses Below 200 Day Moving Average - Should You Sell?

Key Points

• Venture Life Group shares fell below their 200-day moving average, trading as low as GBX 66 versus the average of GBX 66.13, with 17,672 shares changing hands.
• The company reported quarterly EPS of GBX 4.10, a 17.42% net margin and 7.82% return on equity; analysts expect full-year EPS of GBX 6.14.
• Insider Daniel Wells bought 14,760 shares at GBX 68, while insiders collectively own 7.65% of the company—potentially signaling some internal confidence despite the technical weakness.

Venture Life Group plc (LON:VLG - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of GBX 66.13 and traded as low as GBX 66. Venture Life Group shares last traded at GBX 66, with a volume of 17,672 shares.

Venture Life Group Stock Performance

The stock's 50-day moving average price is GBX 67.30 and its 200-day moving average price is GBX 66.13. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.48 and a current ratio of 4.71. The company has a market capitalization of £78.29 million, a price-to-earnings ratio of 15.10, a P/E/G ratio of 5.67 and a beta of 0.23.

Venture Life Group (LON:VLG - Get Free Report) last announced its quarterly earnings results on Tuesday, September 29th. The company reported GBX 4.10 EPS for the quarter. Venture Life Group had a return on equity of 7.82% and a net margin of 17.42%. As a group, equities research analysts expect that Venture Life Group plc will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Daniel Wells bought 14,760 shares of Venture Life Group stock in a transaction on Thursday, October 1st. The shares were bought at an average cost of GBX 68 per share, for a total transaction of £10,036.80. Corporate insiders own 7.65% of the company's stock.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.